Top 25 Biotech Companies of 2013 - Printable Version +- Biotechnology Forums (https://www.biotechnologyforums.com) +-- Forum: Education and Careers (https://www.biotechnologyforums.com/forum-26.html) +--- Forum: Careers (https://www.biotechnologyforums.com/forum-13.html) +--- Thread: Top 25 Biotech Companies of 2013 (/thread-2884.html) |
Top 25 Biotech Companies of 2013 - sale0303 - 01-07-2014 • #1. Novo Nordisk 2013 Market Cap: $85.335 billion (7/2: 535.0 million shares * price DKK 911.50)1,10 2012 Market Cap: $62.809 billion (7/2: 418.0 million shares * price DKK 859.00)1,10 % Change: 35.9% Position on 2012 List: #1 • #2. Amgen 2013 Market Cap: $78.695 billion (4/24: 749,976,556 shares * price $104.93) 2012 Market Cap: $55.054 billion (4/26: 777,707,877 shares * price $70.79) % Change: 42.9% Position on 2012 List: #2 • #3. Gilead Sciences 2013 Market Cap: $78.373 billion (4/26: 1,525,355,825 shares * price $51.38) 2012 Market Cap: $19.751 billion (4/27: 757,321,824 shares * price $26.08) % Change: 296.8% Position on 2012 List: #3 • #4. Celgene 2013 Market Cap: $52.557 billion (4/23: 417,122,477 shares * price $126.00) 2012 Market Cap: $34.319 billion (4/25: 440,497,817 shares * price $77.91) % Change: 53.1% Position on 2012 List: #7 • #5. Biogen Idec 2013 Market Cap: $47.157 billion (4/18: 237,374,815 shares * price $198.66) 2012 Market Cap: $31.582 billion (5/1: 239,562,899 shares * price $131.83) % Change: 49.3% Position on 2012 List: #4 • #6. Teva Pharmaceutical Industries 2013 Market Cap: $33.768 billion (3/31: About 851 million shares * price $39.68 on 3/28)4,9 2012 Market Cap: $39.292 billion (3/31: About 872 million shares * price $45.06 on 3/30)4,9 % Change: -14.1% Position on 2012 List: #5 • #7. Merck KGaA 2013 Market Cap: $33.364 billion (3/31: 217,388,939 shares * price €117.70 on 3/29)4 2012 Market Cap: $22.319 billion (3/31: 217,388,939 shares * price €78.72 on 3/30)4 % Change: 49.5% Position on 2012 List: #8 • #8. CSL 2013 Market Cap: $27.440 billion (6/30: A$30.042 billion) (dd)1,8 2012 Market Cap: $18.359 billion (6/30: A$20.099 billion) (dd)1,8 % Change: 49.5% Position on 2012 List: #9 • #9. Regeneron 2013 Market Cap: $20.269 billion (4/17: 95,122,401 shares * price $213.08)7 2012 Market Cap: $11.894 billion (4/11: 97,966,145 shares * price $121.41)7 % Change: 70.4% Position on 2012 List: #12 • #10. Alexion 2013 Market Cap: $17.893 billion (4/23: 195,146,634 shares * price $91.69) 2012 Market Cap: $17.152 billion (4/20: 186,924,017 shares * price $91.76) % Change: 4.3% Position on 2012 List: #10 • #11. Shire 2013 Market Cap: $17.252 billion (4/29: 562,826,237 shares * price £20.17) 2012 Market Cap: $17.205 billion (4/27: 562,532,330 shares * price £20.13 on 4/26) % Change: 0.3% Position on 2012 List: Not on list • #12. Vertex Pharmaceuticals 2013 Market Cap: $17.495 billion (4/26: 221,400,864 shares * price $79.02) 2012 Market Cap: $8.151 billion (4/27: 211,061,148 shares * price $38.62) % Change: 114.6% Position on 2012 List: #11 • #13. UCB 2013 Market Cap: $11.650 billion (3/31: 179.3 million shares * price €49.80 on 3/29)1,6 2012 Market Cap: $7.449 billion (3/31: 176.4 million shares * price €32.35 on 3/30)1,6 % Change: 56.4% Position on 2012 List: #14 • #14. BioMarin Pharmaceutical 2013 Market Cap: $9.097 billion (4/19: 139,010,175 shares * price $65.44) 2012 Market Cap: $3.788 billion (4/13: 115,700,983 shares * price $32.74) % Change: 140.2% Position on 2012 List: #16 • #15. Elan 2013 Market Cap: $7.041 billion (3/31: about 596.7 million shares * price $11.80 on 3/28)4,5 2012 Market Cap: $8.868 billion (3/31: about 590.8 million shares * price $15.01 on 3/30)4,5 % Change: -20.6% Position on 2012 List: #15 • #16. Actelion 2013 Market Cap: $6.885 billion (3/31: 126.7 million shares * price CHF 51.55)1,3 2012 Market Cap: $4.548 billion (3/31: 130.7 million shares * price CHF 33.00)1,3 % Change: 51.4% Position on 2012 List: #20 • #17. Onyx Pharmaceuticals 2013 Market Cap: $6.580 billion (5/3: 72,738,263 shares * price $90.46) 2012 Market Cap: $3.010 billion (4/27: 64,369,185 shares * price $46.76) % Change: 118.6% Position on 2012 List: #19 • #18. Dr. Reddy’s Laboratories 2013 Market Cap: $5.014 billion (3/31: 169,836,475 shares * price Rs. 1766.50 on 3/29)1,2 2012 Market Cap: $5.001 billion (3/31: 169,560,346 shares * price Rs. 1764.75 on 3/30)1,2 % Change: 0.3% Position on 2012 List: #17 • #19. Seattle Genetics 2013 Market Cap: $4.390 billion (5/2: 121,265,608 shares * price $36.20) 2012 Market Cap: $2.316 billion (5/2: 117,051,559 shares * price $19.79) % Change: 89.6% Position on 2012 List: #25 • #20. Alkermes 2013 Market Cap: $4.011 billion (5/8: 134,380,999 shares * price $29.85) 2012 Market Cap: $2.356 billion (5/11: 130,241,192 shares * price $18.09) % Change: 70.2% Position on 2012 List: Not ranked • #21. Ariad Pharmaceuticals 2013 Market Cap: $3.300 billion (4/30: 184,690,546 shares * price $17.87) 2012 Market Cap: $2.701 billion (4/30: 165,728,859 shares * price $16.30) % Change: 22.2% Position on 2012 List: #24 • #22. Cubist Pharmaceuticals 2013 Market Cap: $3.059 billion (4/22: 65,206,393 shares * price $46.91) 2012 Market Cap: $2.668 billion (4/19: 63,337,315 shares * price $42.13) % Change: 14.7% Position on 2012 List: Not ranked • #23. United Therapeutics 2013 Market Cap: $2.966 billion (4/18: 49,707,574 shares * price $59.67) 2012 Market Cap: $2.260 billion (4/20: 53,685,360 shares * price $42.09) % Change: 31.2% Position on 2012 List: Not ranked • #24. Ipsen Group 2013 Market Cap: $2.889 billion (3/1: 84,100,253 shares * price €26.24)1 2012 Market Cap: $2.230 billion (3/1: 84,226,573 shares * price €20.26)1 % Change: 29.6% Position on 2012 List: Not ranked • #25. Isis Pharmaceuticals 2013 Market Cap: $2.324 billion (5/2: 103,780,421 shares * price $22.39) 2012 Market Cap: $803.473 million (5/3: 100,183,683 shares * price $8.02) % Change: 189.2% Position on 2012 List: Not ranked RE: Top 25 Biotech Companies of 2013 - kaamil20 - 04-03-2014 I've been skeptical of Isis Pharmaceuticals because of the twisted path that its drug Kynamro took to market, at first appearing like it might be a big opportunity and then having expectations repeatedly cut as a competitor emerged. |